Waters Q3 sales rise 8% to $800 million; raises 2025 non-GAAP EPS guidance
Waters reported third-quarter 2025 sales of $800 million, up 8% from $740 million a year earlier, and non-GAAP EPS of $3.40, up 16% from $2.93. GAAP diluted EPS was $2.50, down from $2.71. The company raised its full-year 2025 non-GAAP EPS guidance to $13.05 to $13.15, which matters to shareholders because it reflects higher expected earnings for the year, though GAAP EPS declined.
Key points
- Q3 2025 sales of $800 million, up 8% as reported and 8% in constant currency; Pharmaceutical sales rose 12% as reported
- GAAP diluted EPS of $2.50 versus $2.71 a year earlier; non-GAAP EPS of $3.40 versus $2.93, up 16%
- Full-year 2025 non-GAAP EPS guidance raised to $13.05 to $13.15; constant currency sales growth guidance raised to +6.7% to +7.3%
- Fourth quarter 2025 non-GAAP EPS expected in the range of $4.45 to $4.55
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:30 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.